You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy
SBC: sGC Pharma Inc. Topic: NIADESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A Novel Insulin Pathway Agonist for Alzheimer's Disease
SBC: MEDCHEM PARTNERS LLC Topic: NIADESCRIPTION (provided by applicant): Even though the association of -amyloid peptide (A ) deposition and Alzheimer's Disease (AD) underpins the major hypothesis for disease progression and possibly causation and several drugs addressing the formation or removal of -amyloid plaques have entered clinical trials, no effective therapy exists to date for AD. This reality calls for new targets th ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A noninvasive optical imaging of retinal amyloid beta deposits in AD patients
SBC: NEUROVISION IMAGING, LLC Topic: NIADESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a progressive and invariably fatal degenerative dementia and the most common form of dementia that currently affects over 5 million Americans. The quality of life and economic costs are significant with estimated U.S. health care payments of over 200 billion in 2012, plus unpaid care by over 15 million Americans that is valued ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the Innate Immune System by Fisetin for the Treatment of AD
SBC: VIROGENICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatm ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
An intravaginal ring for real-time evaluation of adherence to topical vagina
SBC: AURITEC PHARMACEUTICALS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The broad long-term of this project is to develop methods for evaluation of adherence to intravaginal microbicide therapy for the prevention of HIV transmission. Correct determination of adherence to preventative therapies in clinical trials is essential to accurate evaluation of efficacy. A better understanding of the true adherence to a preventative therapy w ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of
SBC: AARDEN PHARMACEUTICALS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of tuberculosis Aarden Pharmaceuticals Project Summary/Abstract The need exists for a new, breakthrough therapeutic for tuberculosis (TB). Current treatment regimens with toxic chemotherapeutic drugs are too long, causing poor compliance which results in reduced efficacy and the emer ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Identification and Validation of Targets of Phenotypic High Throughput Screening
SBC: COLLABORATIVE DRUG DISCOVERY, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Identification and Validation of Targets of Phenotypic High Throughput Screening Hits for Chagas Disease Project Summary Nearly 10 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the causative agent of Chagas disease. The World Health Organization (WHO) classifies Chagas disease as a neglected tropical disease, but C ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Novel indication for myeloid progenitor use: Induction of tolerance
SBC: Cellerant Therapeutics, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): State of the art techniques result in 10-year solid organ graft loss of up to 80% in cardiopulmonary organ transplantation, and re-transplantation is often not possible. Establishment of donor-specific immunological tolerance (DSIT), a condition in which a recipient accepts a transplant without immunosuppression, while retaining the ability to fight infections, ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Bacterial fermentation in skin microbiome as probiotics (Bfismp) against S. aureu
SBC: Surface Bioadvances, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): Bacterial interference creates an ecological competition between commensal bacteria and pathogenic species. Like microbial competition via fermentation in a ripening fruit, bacterial interference via fermentation has been found in the deep-seated skin abscesses where is an anaerobic microenvironment, allowing bacteria to ferment carbohydrates to short-chain fa ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A Novel Brachytherapy Agent for GBM
SBC: APPLIED INTEGRIN SCIENCES, INC. Topic: NCIDESCRIPTION (provided by applicant): Despite advances in surgery, chemotherapy, and radiation therapy, the average life span of a patient with glioblastoma multiforme (GBM) is about 15-months from time of diagnosis. Integrins are heterodimeric receptors found on the surface of GBM cells and angiogenic vasculature; they facilitate invasion into adjacent tissue. Normal brain tissue does not display ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health